Diabetic Retinopathy
Diabetic retinopathy is a progressive microvascular complication of chronic hyperglycemia that damages the retinal neurovascular unit and, if untreated, culminates in vision-threatening proliferative retinopathy or diabetic macular edema; it is the leading global cause of preventable blindness among working-age adults, affecting more than one-third of people with diabetes.
Symptoms
Early stages are asymptomatic; as disease advances patients may notice fluctuating blurred vision, difficulty focusing, impaired color discrimination, floaters from vitreous hemorrhage, dark or empty areas in the visual field, sudden unilateral vision loss when tractional detachment or dense hemorrhage occurs, and in macular edema central blurring that worsens with reading.
Risk Factors
Duration of diabetes over ten years, poor glycemic control with HbA1c above seven percent, hypertension, dyslipidemia, nephropathy with micro- or macro-albuminuria, pregnancy, puberty, obesity, obstructive sleep apnea, anemia, smoking, African-American or Hispanic ethnicity, rapid improvement in glycemic control after intensive insulin or bariatric surgery, and genetic variants in AKR1B1, VEGFA or HTRA1 that heighten microvascular vulnerability.
Diagnosis
Annual dilated fundus examination or mydriatic retinal photography reveals microaneurysms, intraretinal hemorrhages, hard exudates and venous beading graded by the International Clinical Diabetic Retinopathy scale; optical coherence tomography quantifies retinal-thickness changes and cystoid spaces of macular edema; fluorescein angiography delineates capillary non-perfusion, microaneurysm leakage and neovascularization guiding focal laser; wide-field OCT-angiography detects subclinical ischemia and early proliferative disease; visual acuity charting documents functional impairment; systemic evaluation includes HbA1c, blood pressure, lipid profile and renal function to correlate systemic control with ocular findings.
Treatment
Intensive multifactorial risk-factor management halts progression: maintain HbA1c ≤ 7 % or individualized, control blood pressure < 130/80 mmHg with ACEi or ARB, treat dyslipidemia with high-intensity statin ± fenofibrate which reduces retinopathy progression, encourage weight loss and smoking cessation; ocular-specific therapy depends on severity: diabetic macular edema involving the fovea is first-line treated with intravitreal anti-VEGF agents (aflibercept 2 mg, ranibizumab 0.3 mg, faricimab 6 mg) monthly then treat-and-extend, with corticosteroid implants (dexamethasone 0.7 mg) for refractoriness or pseudophakia; proliferative retinopathy receives panretinal photocoagulation in 1200–1600 burns or monthly anti-VEGF injections as alternative or adjunct; vitreous hemorrhage or tractional detachment threatening the macula warrants pars plana vitrectomy with membrane peeling and endolaser; neuroprotective trials with brimonidine or ciliary neurotrophic factor implants are under investigation; tele-ophthalmology screening with AI grading improves early detection.
Outlook
Early detection and timely therapy reduce severe vision loss by over ninety percent, but one in four patients still develop vision-threatening disease without regular screening; strict metabolic control from diagnosis halves retinopathy incidence in type-1 and slows progression in type-2, yet residual risk persists due to metabolic memory; anti-VEGF therapy stabilizes vision in ninety percent and improves by ≥ three lines in forty percent, while untreated proliferative disease carries a five-year blindness risk of fifty percent.
Complications
Severe non-proliferative and proliferative retinopathy with vitreous hemorrhage, tractional or rhegmatogenous retinal detachment, neovascular glaucoma, diabetic macular edema, cataract acceleration, cognitive decline associations, anxiety and depression from visual disability, driving cessation and work loss constitute major sequelae.
Prevention
Optimal glycemic control from diagnosis, aggressive blood-pressure and lipid management, renin–angiotensin blockade, lifestyle modification, annual retinal screening with digital photography or tele-ophthalmology, and prompt laser or pharmacologic intervention at earliest signs prevent progression to blindness; population strategies include diabetes prevention programs, retinal-camera integration into primary care and insurance coverage of anti-VEGF agents.
Support
Adhere to glucose self-monitoring and medication regimen, follow antihypertensive and lipid-lowering therapy, maintain healthy Mediterranean-style diet rich in leafy greens and omega-3 fatty acids, exercise at least one hundred fifty minutes weekly unless advised to avoid strenuous Valsalva activities in proliferative retinopathy, stop smoking, limit alcohol, use protective eyewear during sports, employ high-contrast reading materials and adequate lighting, and schedule regular eye visits; caregivers can assist with appointment coordination, transport after dilation and reinforcement of medication adherence.
Sources
The information presented above is supported by reputable medical sources and research publications. These references provide additional clinical insights and evidence-based findings for healthcare professionals and individuals seeking comprehensive understanding of this medical condition.
